{"id":"89zr-zr-crefmirlimab-berdoxam","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pemetrexed","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Antiplatelets","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eptifibatide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Prasugrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticagrelor","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tirofiban","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[],"contraindications":["Hypersensitivity to the active substance or to any of the excipients","Pregnancy","Breast-feeding","Severe renal impairment (creatinine clearance < 30 mL/min)"],"specialPopulations":{}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=89zr-zr-crefmirlimab-berdoxam","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:52:55.172146+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:53:00.541936+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:52:55.245217+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=89zr-zr-crefmirlimab-berdoxam","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:53:01.017480+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5314651/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:53:01.730237+00:00"}},"allNames":"[89zr]zr-crefmirlimab berdoxam","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"89Zr-Zr-crefmirlimab berdoxam is a radiolabeled antibody developed by Pfizer Inc. for imaging purposes. It is not approved by the FDA and is currently in the pipeline for various oncology applications. The drug targets fibroblast activation protein (FAP) and is designed to help visualize tumors that express this protein. Due to its radiolabeled nature, it may have specific safety considerations, including radiation exposure. The drug is part of a broader class of targeted radiopharmaceuticals and represents a novel approach in cancer imaging.","brandName":"[89Zr]Zr-crefmirlimab berdoxam","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Fibroblast Activation Protein (FAP)","novelty":"Novel radiolabeled antibody for tumor imaging","modality":"Imaging Agent","drugClass":"Radiolabeled Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"The antibody is labeled with the radioisotope zirconium-89 (89Zr), which emits positrons detectable by PET imaging, providing detailed images of FAP-expressing tumors."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:33.642Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":"Not specified","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Not specified","peakSalesEstimate":"Not specified"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=89zr-zr-crefmirlimab-berdoxam","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=89zr-zr-crefmirlimab-berdoxam","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:03.382326+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Lutathera","company":"Advanced Accelerator Applications","advantage":"Lutathera is a radioligand therapy that targets somatostatin receptors, similar to 89Zr-Zr-Crefmirlimab Berdoxam, but with a different mechanism of action and a different target.","genericName":"Lutetium Lu 177 dotatate"},{"name":"Xofigo","company":"Algeta","advantage":"Xofigo is a radiopharmaceutical that targets bone metastases, similar to 89Zr-Zr-Crefmirlimab Berdoxam, but with a different mechanism of action and a different target.","genericName":"Radium Ra 223 dichloride"},{"name":"Pluvicto","company":"Novartis","advantage":"Pluvicto is a radioligand therapy that targets prostate-specific membrane antigen (PSMA), similar to 89Zr-Zr-Crefmirlimab Berdoxam, but with a different mechanism of action and a different target.","genericName":"Lutetium Lu 177 vipivotide tetraxetan"}],"genericName":"89zr-zr-crefmirlimab-berdoxam","indications":{"approved":[{"name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","regulator":"FDA"}],"offLabel":[],"pipeline":["Oncology Imaging"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06534190","phase":"PHASE2","title":"CD8 PET Imaging in Metastatic Solid Tumours","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2025-03-11","conditions":"Locally Advanced Solid Tumor","enrollment":30},{"nctId":"NCT06650163","phase":"PHASE1","title":"Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-12-05","conditions":"Glioma, Malignant Brain Neoplasm, Meningioma","enrollment":20},{"nctId":"NCT05371132","phase":"PHASE1","title":"Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-20","conditions":"Metastatic Malignant Solid Neoplasm, Lymphoma","enrollment":10},{"nctId":"NCT05279027","phase":"EARLY_PHASE1","title":"Zr89 + PET Companion Trial","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-03-08","conditions":"Melanoma (Skin)","enrollment":6},{"nctId":"NCT05744128","phase":"PHASE2","title":"CD8 Minibody Repeatability Study","status":"TERMINATED","sponsor":"ImaginAb, Inc.","startDate":"2023-02-16","conditions":"Melanoma, Renal Cell Carcinoma","enrollment":3},{"nctId":"NCT06218069","phase":"PHASE2, PHASE3","title":"Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2025-02","conditions":"NSCLC","enrollment":20},{"nctId":"NCT05013099","phase":"PHASE2","title":"Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImaginAb, Inc.","startDate":"2021-12-09","conditions":"Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma","enrollment":70}],"_emaApprovals":[{"date":"","name":"[89Zr]Zr-crefmirlimab berdoxam","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5314651","moleculeType":"Antibody drug conjugate","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5314651"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Monoclonal antibody","firstApprovalDate":"Not specified","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:53:03.382326+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}